Alumis Stock

alumis.comHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $638.43MM

Alumis is a biotechnology company focused on developing treatments for autoimmune disease, and their goal is to create therapies that are more precise than currently available autoimmune or immune-mediated disease treatments. Alumis was founded in 2021 and is headquartered in San Francisco, CA. Through its data analytics platform, Alumis seeks to enable researchers to match the right patients to targets, molecules, and combinations so they can create the best possible outcomes.

Register To Buy and Sell Shares

For more details on financing and valuation for Alumis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Alumis’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Alumis.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Mark Bradley
Chief Development Officer
Martin Babler
Chief Executive Officer & President
John Schroer
Chief Financial Officer
David Zhang Ph.D
Chief Information Officer & Senior Vice President of Biometrics and Data Management
Roy Hardiman JD
Chief Business and Legal Officer & General Counsel
David Goldstein Ph.D
Chief Scientific Officer & Head of Chemistry, Manufacturing, and Controls
Jörn Drappa Ph.D
Chief Medical Officer

Board Members

Alan Colowick MD
Matrix Capital Management
James Tananbaum MD
Foresite Capital
Michael Rome Ph.D
Foresite Capital
Richard Gaster Ph.D
Srinivas Akkaraju Ph.D
Samsara BioCapital
Vikram Bajaj Ph.D
Foresite Capital

Frequently Asked Questions About Alumis’ Stock

Can you buy Alumis’ stock?
Alumis is not publicly traded on NYSE or NASDAQ in the U.S. To buy Alumis’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Alumis’ stock?
Yes, you can sell stock of a private company like Alumis. Forge can help you sell your Alumis stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Alumis’ stock price?
Alumis is a privately held company and therefore does not have a public stock price. However, you may access Alumis’ private market stock price with Forge Data.
What is Alumis’ stock ticker symbol?
Alumis does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
In a series C funding round led by Foresite Capital and others, Alumis closed a deal of $259 million in financing for their oral therapy development,
Alumis closes $259M series C in year's largest private biotech fundraise yet
In new series C funding, Alumis raised $259 million to launch a new immune therapy trial.
Updated on: Jun 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.